Scarica l'app Stockscreener
1.18
2.48%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.21
Aprire:
$1.22
Volume 24 ore:
501.25K
Relative Volume:
0.14
Capitalizzazione di mercato:
$122.01M
Reddito:
$65,300
Utile/perdita netta:
$-84.93M
Rapporto P/E:
-0.6909
EPS:
-1.708
Flusso di cassa netto:
$-83.57M
1 W Prestazione:
-4.84%
1M Prestazione:
-8.53%
6M Prestazione:
-23.38%
1 anno Prestazione:
-51.44%
Intervallo 1D:
$1.18
$1.23
Intervallo di 1 settimana:
$1.18
$1.335
Portata 52W:
$0.5632
$2.72
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Nome
Inovio Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 410-3134
Indirizzo
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.18 | 125.11M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
521.13 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.95 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.22 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.17 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.81 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Piper Sandler | Overweight |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-01-25 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Downgrade | Maxim Group | Buy → Hold |
| 2022-11-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Ripresa | Jefferies | Hold |
| 2021-09-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Iniziato | Jefferies | Hold |
| 2021-03-23 | Iniziato | BofA Securities | Neutral |
| 2021-02-12 | Iniziato | Oppenheimer | Outperform |
| 2020-11-17 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Aggiornamento | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-01 | Downgrade | Maxim Group | Buy → Hold |
| 2020-07-01 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Downgrade | Stifel | Buy → Hold |
| 2020-05-21 | Iniziato | The Benchmark Company | Buy |
| 2020-04-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Iniziato | ROTH Capital | Buy |
| 2018-02-15 | Reiterato | Maxim Group | Buy |
| 2017-10-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-06 | Iniziato | Citigroup | Buy |
| 2017-06-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Reiterato | Maxim Group | Buy |
| 2017-03-16 | Aggiornamento | Maxim Group | Hold → Buy |
| 2017-03-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Mostra tutto
Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (INO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance UK
Inovio Pharmaceuticals stock trades lower as FDA date nears - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INO Looks 490.5% Overvalued on GF Value™ - GuruFocus
Inovio Pharmaceuticals stock gains as price crosses 200-day moving average - AD HOC NEWS
Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view - AD HOC NEWS
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com South Africa
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - es.tradingview.com
Inovio at H.C. Wainwright conference: FDA review and launch loom - Investing.com India
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - TradingView
INOVIO at Cantor Fitzgerald healthcare conference: FDA decision nears By Investing.com - Investing.com India
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO Steps Up Investor Outreach at New York Conferences - MyChesCo
INO Stockholders Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INOVIO to Participate in Upcoming Investor Conferences - Eastern Progress
Inovio Pharmaceuticals Stock Price Forecast. Should You Buy INO? - StockInvest.us
Inovio Pharmaceuticals stock gains as analysts see sharp upside - ad-hoc-news.de
Investor talks begin Sept. 9 as INOVIO joins two conferences - Stock Titan
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio stock holds in low single digits as losses weigh on outlook - ad-hoc-news.de
Inovio Pharmaceuticals Inc (NASDAQ: INO) Share Price, INO Stock News, INO Share Price & Updates - kalkine.ca
Inovio Pharmaceuticals Inc. (INO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Inovio: The Final Countdown To A Binary FDA Decision - Seeking Alpha
Inovio Pharmaceuticals Inc. Stock Rises 5.9%, Outperforms Peers - Bitget
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio (INO) Results Versus Estimates: Profit Per Share Clears Its Benchmark in Latest Trading; Market Response: The Stock Ends Down 6.92%Pre-Earnings Setup - Vinanet
Inovio Pharmaceuticals Company Profile & Introduction - Moomoo
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Inovio Pharmaceuticals Inc. Stock Rallies 8.3%, Outperforms Peers - Bitget
Inovio (INO) Earnings Check: The Available Earnings Metric Delivers a Beat at the Close; Post-Report Move: The Stock Ends Up 4.35% in the Latest ReadingFinancial Data - Vinanet
Inovio Pharmaceuticals Inc. Stock Rallies 5.5%, Outperforms Peers - Bitget
Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst - MarketBeat
INO Jumps As Inovio Wins Upgrade Ahead Of FDA Decision - timothysykes.com
Inovio Stock Jumps As Jefferies Upgrade Bets On FDA Decision - StocksToTrade
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen - MarketBeat
INOVIO Sets Aug. 12 Earnings Update With Business Review - MyChesCo
Inovio Pharmaceuticals Highlights FDA Inspection Completion and INO-3107 Regulatory Progress in Q2 2026 Earnings CallDividend Earnings Report - Vinanet
HC Wainwright Issues Negative Estimate for INO Earnings - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Kura Oncology (KURA) and Inovio Pharmaceuticals (INO) - The Globe and Mail
INO Upgraded by Jefferies -- Price Target Raised to $3.00 - GuruFocus
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Jefferies Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Raises Target Price to $3 - Moomoo
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target - Investing.com
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target By Investing.com - Investing.com Canada
Jefferies upgrades Inovio stock rating on FDA review progress - Investing.com
Inovio Q2 2026 slides: INO-3107 on track for Oct FDA decision - Investing.com Nigeria
Jefferies upgrades Inovio stock rating on FDA review progress By Investing.com - Investing.com Canada
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Inovio Pharmaceuticals Inc Azioni (INO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):